News

Media

Conferences

Publications

Clinical

Events

Resources

Precision Perspectives: Navigating Advancements in HR+ / HER2 Negative Breast Cancer Care : Episode 18

Opinion

Video

June 18, 2024

Navigating Therapy Approval for Early Breast Cancer: An Operational Perspective

Author(s):

Ryan Haumschild, PharmD, MS, MBA,Heather Moore, BCOP, CPP, PharmD

Medical experts discuss their perspectives on therapy approval and the significance of formulary inclusion, emphasizing the need to carefully consider both toxicities and benefits, which may ultimately lead to the operationalization of a drug in clinical practice.

EP: 1.Optimizing Adherence to CDK4/6 Inhibitors in Metastatic Breast Cancer

EP: 2.Institutional Insights on CDK4/6 Inhibitor Adherence in Breast Cancer

EP: 3.CDK4/6 Inhibitors as First-Line Options in Metastatic Breast Cancer

EP: 4.Treatment Algorithms for Early and Metastatic Breast Cancer

EP: 5.NATALEE: Ribociclib and Endocrine Therapy in HR+/HER2- Early Breast Cancer

EP: 6.Evaluating the Impact of Metastatic Breast Cancer on Patients

EP: 7.Highlighting the Available CDK4/6 Inhibitors

EP: 8.Strategies to Enhance CDK4/6 Inhibitor Adherence in mBC

EP: 9.Applying NCCN Guidelines in the Treatment of mBC

EP: 10.CDK4/6 Inhibitor Sequencing and NCCN Guidelines in mBC

EP: 11.Evaluating CDK4/6 Inhibitor Safety Profiles: An Analysis of Adverse Events

EP: 12.Navigating Financial Barriers: Cost-Saving Strategies and Patient Assistance Programs

EP: 13.Exploring Therapeutic Alternatives to CDK4/6 Inhibitors in Metastatic Breast Cancer

EP: 14.Academic and Community Practice Collaboration in mBC Treatment

EP: 15.Defining the Standard of Care for Early Breast Cancer Treatment

EP: 16.Balancing Clinical and Economic Factors in Early Breast Cancer Treatment

EP: 17.Alternative Treatments for eBC and mBC

EP: 18.Navigating Therapy Approval for Early Breast Cancer: An Operational Perspective

EP: 19.Bridging the Gap: Multidisciplinary Collaboration in Early Breast Cancer Care

EP: 20.Key Takeaways on mBC and eBC

Video content above is prompted by the following questions:

How will the potential approval of ribociclib for early breast cancer change your treatment paradigms?

Related Videos

5 experts in this video

5 experts in this video

5 experts in this video

5 experts in this video

This series features 5 KOLs.

This series features 5 KOLs.

This series features 5 KOLs.

This series features 5 KOLs.

This series features 5 KOLs.

This series features 5 KOLs.

Consent Preferences

Clinical Forums

Editorial Staff

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.